Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Ishares Genomics Immunology and Healthcare ETF (IDNA)

Ishares Genomics Immunology and Healthcare ETF (IDNA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Moderna Turns Red Hot: Biotech ETFs to Bet On

Moderna skyrocketed 245% since it announced its COVID-19 vaccine candidate mRNA-1273 on Feb 10. The solid run is likely to continue as most of the analysts are optimistic on the stock.

MRNA : 74.10 (+0.46%)
IBB : 136.23 (-0.39%)
CNCR : 26.19 (unch)
XBI : 113.92 (+0.10%)
BBH : 164.12 (-0.29%)
BTEC : 45.81 (-0.07%)
IDNA : 38.47 (-0.18%)
GERM : 32.45 (unch)
Moderna Inches Closer to Coronavirus Vaccine: ETFs to Shine

Moderna plans to begin the Phase 3 study of mRNA-1273 this month.

PFE : 38.45 (+0.47%)
MRNA : 74.10 (+0.46%)
IBB : 136.23 (-0.39%)
CNCR : 26.19 (unch)
XBI : 113.92 (+0.10%)
BBH : 164.12 (-0.29%)
FBT : 166.33 (+0.02%)
BTEC : 45.81 (-0.07%)
IDNA : 38.47 (-0.18%)
GERM : 32.45 (unch)
How to Tap Red-Hot Moderna Stock With ETFs

Moderna shares have surged more than 280% so far this year on the positive development of coronavirus vaccine.

MRNA : 74.10 (+0.46%)
IBB : 136.23 (-0.39%)
CNCR : 26.19 (unch)
XBI : 113.92 (+0.10%)
BBH : 164.12 (-0.29%)
BTEC : 45.81 (-0.07%)
IDNA : 38.47 (-0.18%)
GERM : 32.45 (unch)
Top-Performing Biotechnology ETFs Amid Coronavirus Outbreak

From vaccine-related progress to development of cell therapies for the treatment of coronavirus, all kept the rally in the biotech sector alive.

BIB : 71.52 (-0.74%)
XBI : 113.92 (+0.10%)
ARKG : 56.18 (-2.70%)
IDNA : 38.47 (-0.18%)
Invest in the Future With Megatrend ETFs

These ETFs invest in fast growing areas like robotics and AI, genomics and cybersecurity.

REGN : 620.21 (-0.16%)
GILD : 69.35 (+0.78%)
MRNA : 74.10 (+0.46%)
IRBO : 32.20 (-1.59%)
TECB : 31.11 (-1.37%)
IHAK : 33.49 (-1.22%)
IDNA : 38.47 (-0.18%)
Moderna a Step Closer to Coronavirus Vaccine: ETFs to Gain

Moderna informs that the final-stage trial's primary aim will be to prevent the spread of coronavirus.

JNJ : 148.60 (+0.71%)
AZN : 55.41 (-1.42%)
MRNA : 74.10 (+0.46%)
IBB : 136.23 (-0.39%)
CNCR : 26.19 (unch)
XBI : 113.92 (+0.10%)
BBH : 164.12 (-0.29%)
IDNA : 38.47 (-0.18%)
Profit from the Genomics Market Momentum With These ETFs

Here we highlight some ETFs for gaining exposure to the genomics market that is currently buzzing with opportunities for investors to cash on.

GSK : 40.79 (-0.44%)
PBE : 61.17 (+1.07%)
ARKG : 56.18 (-2.70%)
GNOM : 18.17 (-0.90%)
IDNA : 38.47 (-0.18%)
Is Moderna Winning the COVID-19 Vaccine Race? ETFs to Gain

Moderna has presented positive interim data from a phase I study evaluating its mRNA-based coronavirus vaccine candidate.

JNJ : 148.60 (+0.71%)
SNY : 51.51 (+0.02%)
AZN : 55.41 (-1.42%)
MRNA : 74.10 (+0.46%)
GSK : 40.79 (-0.44%)
NVAX : 170.29 (+1.67%)
IBB : 136.23 (-0.39%)
CNCR : 26.19 (unch)
XBI : 113.92 (+0.10%)
BBH : 164.12 (-0.29%)
IDNA : 38.47 (-0.18%)
Healthcare & Biotech ETFs Digest GILD's Failure News: 5 Winners

Biotech and healthcare ETFs were pretty stable on Apr 23 despite the news that Gilead's Remdesivir failed to improve Covid-19 patients' condition.

GILD : 69.35 (+0.78%)
IBB : 136.23 (-0.39%)
CNCR : 26.19 (unch)
BBH : 164.12 (-0.29%)
FBT : 166.33 (+0.02%)
PTH : 142.34 (-0.17%)
IHF : 208.67 (+0.71%)
IHE : 163.82 (+0.43%)
XPH : 44.73 (+0.58%)
SBIO : 41.47 (+0.90%)
XHS : 78.16 (+0.51%)
PBE : 61.17 (+1.07%)
IDNA : 38.47 (-0.18%)
Coronavirus Scare Supports These Biotech ETFs & Stocks

Growing coronavirus concerns provide some support to these biotech ETFs and stocks amid a massive market sell-off.

IBB : 136.23 (-0.39%)
CNCR : 26.19 (unch)
BBH : 164.12 (-0.29%)
ARKG : 56.18 (-2.70%)
AYTU : 1.3800 (-0.72%)
FTSV : 95.51 (+0.05%)
VIR : 52.03 (+3.73%)
IDNA : 38.47 (-0.18%)
CODX : 25.73 (-1.61%)
CNTG : 12.80 (+1.91%)
11-Year Bull Market Nears an End? ETFs That Should Survive

An oil collapse sent Wall Street into a tailspin on Mar 9, indicating that the 11-year-long bull market might soon end. These ETFs may, however, survive the crash.

PSK : 43.16 (+0.26%)
CLIX : 90.33 (-0.02%)
IDNA : 38.47 (-0.18%)
Wall Street in Correction: 4 Sector ETFs Unscathed in February

These sector ETFs gained or lost the least in the coronavirus-induced rout in February.

TSLA : 1,452.71 (-2.48%)
GLD : 190.81 (-1.59%)
ENPH : 72.84 (+2.06%)
SEDG : 211.47 (+2.50%)
TAN : 51.20 (+2.15%)
SGDM : 36.72 (-3.27%)
CLIX : 90.33 (-0.02%)
KURE : 35.51 (-2.20%)
CNRG : 63.25 (+1.75%)
IDNA : 38.47 (-0.18%)
Will Biotech ETFs Excel in Election Year Post a Surge in 2019?

Can biotech ETFs repeat its success story of 2019 in the election year of 2020?

CNCR : 26.19 (unch)
BBC : 41.33 (+1.13%)
PBE : 61.17 (+1.07%)
IBB : 136.23 (-0.39%)
XBI : 113.92 (+0.10%)
SBIO : 41.47 (+0.90%)
IDNA : 38.47 (-0.18%)
HTEC : 34.44 (-1.09%)
Genomics ETFs Surge on CRISPR's Gene Editing Progress

The release of encouraging data on the CRISPR/Cas9 gene-editing therapy CTX001 for two severe blood disorders puts emphasis on some genomic ETFs.

PBE : 61.17 (+1.07%)
VRTX : 272.99 (-0.13%)
CRSP : 89.81 (-3.37%)
ARKG : 56.18 (-2.70%)
IDNA : 38.47 (-0.18%)
GNOM : 18.17 (-0.90%)
Value Biotech ETFs & Stocks to Buy Now

Biotech valuation looks attractive amid a volley of good news. Investors can tap these stocks and ETFs.

ABBV : 92.92 (+0.38%)
BMY : 61.02 (-0.51%)
MRK : 81.02 (-0.04%)
RHHBY : 43.0100 (-0.97%)
LLY : 152.93 (+0.03%)
GSK : 40.79 (-0.44%)
XBI : 113.92 (+0.10%)
BBH : 164.12 (-0.29%)
AMGN : 240.69 (-0.36%)
BIIB : 305.71 (+10.10%)
CELG : 108.24 (+0.10%)
IDNA : 38.47 (-0.18%)
ETFs Poised to Benefit from Gene Editing Revolution

Rising investments and growing technological advancement are favoring the genomic editing space. We take a look at a few ETFs that can cash in on this trend.

AGN : 193.02 (+0.02%)
PBE : 61.17 (+1.07%)
ONCE : 110.05 (-3.10%)
EDIT : 34.71 (-5.78%)
ARKG : 56.18 (-2.70%)
GNOM : 18.17 (-0.90%)
IDNA : 38.47 (-0.18%)
ETFs to Gain From the Booming Genomics Market

Rising investments, surging demand for personalized medicines and shrinking sequencing costs are a slew of factors favouring the genomics space. We look at a few ETFs that can cash in on this trend.

PBE : 61.17 (+1.07%)
ILMN : 355.66 (-10.94%)
IDNA : 38.47 (-0.18%)
GNOM : 18.17 (-0.90%)
ARKG : 56.18 (-2.70%)

Van Meerten Stock Picks

The 5 Best MidCaps
I wanted to find the 5 Mid Caps that have had the best momentum over the past year so I used Barchart to sort the S&P 400 MidCap Stock Index for the stocks with the highest Weighted Alpha and technical buying signals.
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.

InsideFutures Commentary

InsideFutures is a twice weekly newsletter that features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Wednesday and Friday morning to your inbox.

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar